 |
|
Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Patients With Age-Related Macular Degeneration
Additional Information Regarding Baseline Lesion Composition's Impact on Vision Outcomes—TAP Report No. 3
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group
Arch Ophthalmol. 2002;120:1443-1454.
Objective To explore how baseline lesion composition influenced vision outcomes in patients with age-related macular degeneration (AMD) undergoing photodynamic therapy with verteporfin (Visudyne) for subfoveal choroidal neovascularization (CNV) in the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy Investigation.
Methods Patients with subfoveal lesions secondary to AMD with evidence of classic CNV were categorized into 2 subgroups based on baseline color photographs and fluorescein angiograms assessed by graders at the Wilmer Photograph Reading Center (The Johns Hopkins University School of Medicine) before any outcome analyses as follows: (1) predominantly classic CNV (area of classic CNV  50% of the area of the entire lesion) or (2) minimally classic CNV (area of classic CNV <50% but >0% of the area of the entire lesion). Additional exploratory analyses were performed in the predominantly classic subgroup to investigate the effects of visual acuity, lesion size, prior laser photocoagulation, phakic status, micronutrient use, and presence of occult CNV on vision outcomes.
Main Outcome Measures Subgroup analyses of vision and fluorescein angiographic outcomes at 1 and 2 years after study enrollment were examined in an intent-to-treat analysis from 2 multicenter, double-masked, placebo-controlled, randomized clinical trials.
Results Compared with patients who had minimally classic CNV, patients with predominantly classic CNV had a worse initial mean visual acuity and smaller lesions and were more likely to have lesions that included blood or blocked fluorescence. When evaluated by treatment assignment and lesion composition, 84% to 88% completed the month 24 examination. In the subgroup with predominantly classic lesions, visual acuity outcomes were consistently better in verteporfin-treated patients. Outcomes for patients with predominantly classic lesions without occult CNV tended to be better than outcomes for patients with predominantly classic lesions with occult CNV, although the former tended to have smaller lesions and lower levels of visual acuity at baseline. Contrast sensitivity and fluorescein angiographic outcomes (total lesion size, progression of classic CNV, and absence of classic CNV) were better in verteporfin-treated patients than in placebo-treated patients in the predominantly classic and the minimally classic CNV subgroups. In patients with predominantly classic CNV, no interaction of the treatment benefit by phakic status, micronutrient use, or prior laser photocoagulation therapy was noted.
Conclusions Verteporfin therapy can safely reduce the risk of moderate and severe vision loss in patients with subfoveal lesions that are predominantly classic CNV secondary to AMD. While this benefit seemed to be even greater in the absence of occult CNV, the effect may be related to the smaller lesions and worse visual acuity associated with predominantly classic lesions without occult CNV and not solely to the lesion composition itself. These analyses support initial reports that verteporfin therapy should be used to treat patients with AMD who have predominantly classic CNV, with or without occult CNV, but suggest that further investigations should be performed to determine if lesions with a minimally classic composition might benefit when they are smaller and have lower levels of visual acuity.
The authors for the Writing Committee for this report of the TAP Study Group include Neil M. Bressler, MD; Jennifer Arnold, FRACO; Mustapha Benchaboune, MD; Mark S. Blumenkranz, MD; Gary E. Fish, MD; Evangelos S. Gragoudas, MD; Hilel Lewis, MD; Ursula Schmidt-Erfurth, MD; Jason S. Slakter, MD; Susan B. Bressler, MD; Kelly Manos; Yong Hao, MD, PhD; Laurie Haynes; John Koester; Al Reaves, PhD; and H. Andrew Strong, PhD. Other members of the TAP Study Group, along with their financial disclosures, are published in Arch Ophthalmol. 1999;117:1329-1345, with updates as of January 11, 2000, in Arch Ophthalmol.2001;119:198-207.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Suppression of Choroidal Neovascularization by Dendritic Cell Vaccination Targeting VEGFR2
Mochimaru et al.
IOVS 2007;48:4795-4801.
ABSTRACT
| FULL TEXT
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Raftery et al.
Br. J. Ophthalmol. 2007;91:1244-1246.
ABSTRACT
| FULL TEXT
Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes
Tatar et al.
Br. J. Ophthalmol. 2007;91:166-173.
ABSTRACT
| FULL TEXT
Public Health Impact of Neovascular Age-Related Macular Degeneration Treatments Extrapolated from Visual Acuity
Bandello et al.
IOVS 2007;48:96-103.
ABSTRACT
| FULL TEXT
Estimating the yearly number of eyes with treatable neovascular age-related macular degeneration using a direct standardization method and a markov model.
Korobelnik et al.
IOVS 2006;47:4270-4276.
ABSTRACT
| FULL TEXT
Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study.
Costa et al.
IOVS 2006;47:4569-4578.
ABSTRACT
| FULL TEXT
Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes
Petermeier et al.
Br. J. Ophthalmol. 2006;90:1034-1039.
ABSTRACT
| FULL TEXT
Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes.
Tatar et al.
Arch Ophthalmol 2006;124:815-823.
ABSTRACT
| FULL TEXT
Choroidal neovascularisation in pathological myopia: an update in management
Chan et al.
Br. J. Ophthalmol. 2005;89:1522-1528.
ABSTRACT
| FULL TEXT
Verteporfin Therapy of Subfoveal Minimally Classic Choroidal Neovascularization in Age-Related Macular Degeneration: 2-Year Results of a Randomized Clinical Trial
Visudyne in Minimally Classic Choroidal Neovascula
Arch Ophthalmol 2005;123:448-457.
ABSTRACT
| FULL TEXT
Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration
Arias et al.
Br. J. Ophthalmol. 2005;89:312-315.
ABSTRACT
| FULL TEXT
Photodynamic Therapy With Verteporfin: Observations on the Introduction of a New Treatment Into Clinical Practice
Schein et al.
Arch Ophthalmol 2005;123:58-63.
ABSTRACT
| FULL TEXT
Morphometric Analysis of Angiograms of Exudative Lesions in Age-Related Macular Degeneration
Ali et al.
Arch Ophthalmol 2004;122:710-715.
ABSTRACT
| FULL TEXT
Natural History of Minimally Classic Subfoveal Choroidal Neovascular Lesions in the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Investigation: Outcomes Potentially Relevant to Management--TAP Report No. 6
Bressler et al.
Arch Ophthalmol 2004;122:325-329.
ABSTRACT
| FULL TEXT
Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration
Rechtman et al.
Br. J. Ophthalmol. 2004;88:344-347.
ABSTRACT
| FULL TEXT
Influence of Photodynamic Therapy on Expression of Vascular Endothelial Growth Factor (VEGF), VEGF Receptor 3, and Pigment Epithelium-Derived Factor
Schmidt-Erfurth et al.
IOVS 2003;44:4473-4480.
ABSTRACT
| FULL TEXT
Photodynamic Therapy of Subfoveal Choroidal Neovascularization With Verteporfin: Fluorescein Angiographic Guidelines for Evaluation and Treatment--TAP and VIP Report No. 2
Treatment of Age-Related Macular Degeneration With
Arch Ophthalmol 2003;121:1253-1268.
ABSTRACT
| FULL TEXT
|
